As a result of the eShunt System development process, CereVasc has developed a portfolio of follow-on, novel product concepts that have the potential to improve the care of patients with a variety of neurovascular diseases. The platform has the potential to deliver therapy across the blood-brain barrier, and intended to reduce the uncertainty and complications typically associated with intrathecal injection or ommaya reservoir implantation.
Since inception CereVasc has aggressively pursued patent protection in the United States and abroad for the endovascular treatment of communicating hydrocephalus. To date, the eShunt System development project has generated several issued US patents and additional applications pending in the US and abroad. The Company also has exclusive rights to the original endovascular CSF shunt patent rights and all improvements through a license with Tufts Medical Center, Inc.
Partner with us:
CereVasc is actively seeking pharma and biotechnology partners who desire a novel approach to delivering their CNS therapies.
For more information, contact us.